Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Overview of attention for article published in PharmacoEconomics, March 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source
twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 68 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

baricitinib

Cited by Canadian Agency for Drugs and Technologies in Health on 10 Sep 2019

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.